NCT04508790View on ClinicalTrials.gov

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 27, 2020

Primary Completion Date

February 14, 2027

Study Completion Date

February 14, 2027

Conditions
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
DRUG

Dexamethasone

Given PO

DRUG

Leflunomide

Given PO

DRUG

Pomalidomide

Given PO

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER